Early detection of a mutated p53 gene is thought to provide useful information in a wide range of human tumors. The aim of this study was to identify the role of the p53 gene in transitional cell carcinoma of the urinary tract. From March 1992 to July 2003, 75 patients (54 men and 21 women) with a mean age of 66.85 years and pathologically diagnosed transitional cell carcinoma were enrolled in this study. Fiftyeight patients had bladder cancer, eight had ureteral cancer, and nine had renal-pelvic cancer. Rapid screening for mutation of the p53 gene was performed using polymerase chain reaction (PCR), singlestrand conformation polymorphism (SSCP), and sequencing analysis. Primer sets were designed to amplify fragments within exons 4, 5, 6, 7, and 8 of the p53 gene. Pathology classified 37 tumors as low grade and 38 as high grade. Tumor stage was pT1 or less in 29 patients and at least pT2 in 46 patients. Of the 75 patients in this study, 47 (62.7%) had a p53 mutation. Of the patients with a p53 mutation, 33 (70.2%) had invasive tumors. Invasive tumors were associated with p53 mutation (p < 0.05). Noted in 20 patients (26.7%), exon 4 was the most common site of the mutation. Of the patients with exon 4 mutations, 15 (75%) had invasive tumors and nine (45%) had high-grade tumors. Additionally, among the 20 patients with a common polymorphism at codon 72, 16 (80%) had invasive tumors and 14 (70%) had high-grade tumors. In this study, 62.7% of patients with transitional cell carcinoma had a p53 mutation, suggesting that the p53 gene mutation may be used as a marker of transitional cell carcinoma. Invasive tumors are more likely to have a p53 gene mutation. A simple analysis of the p53 gene using PCR/SSCP is suitable for screening for p53 abnormalities in transitional cell carcinoma. The relationship between cancer risk and the codon 72 polymorphism of exon 4 needs further investigation.
Oncogenic activity or loss of tumor suppressor gene function resulting from genetic alterations, such as mutation, insertion, or deletion, is prevalent in tumor cells and ultimately causes abnormal gene expression. The p53 gene is a well-characterized tumor suppressor gene and is the most frequently altered gene in human cancer. Mutations in p53 occur in approximately 60% of carcinomas. The gene is located in band p13.1 of chromosome 17 and encodes a 53-kd nuclear phosphoprotein involved in the control of cellular proliferation [1] [2] [3] . The p53 protein functions as a sequence-specific transcription factor and is important for the regulation of genes that promote growth arrest or apoptosis in response to cellular stress [4, 5] .
The role of the p53 gene in colon cancer has been studied in great detail. Mutation is most likely within the highly conserved region comprising exons 4-8 [6] . p53 modulates responsiveness to different drugs or treatments [7] . Polymorphism in codon 72 of exon 4 of the p53 gene is associated with the malignancy of colorectal cancer in Taiwanese patients [8] .
Transitional cell carcinoma (TCC) is the fifth most common solid malignancy in the USA. After prostate cancer, TCC of the bladder is the second most common malignancy of the genitourinary tract, and annually accounts for about 54,000 new diagnoses and more than 12,000 deaths in the USA alone [9] . In Taiwan, the incidence of bladder cancer is 2.29/100,000 and accounts for about 400 deaths (1.91/ 100,000) annually [10] . Certain genitourinary cancers (testis cancer, pheochromocytoma, and Wilms tumors) do not commonly manifest p53 mutations, whereas others (bladder and prostate cancers) are frequently associated with p53 alterations [11] . Therefore, TCC of the urinary tract provides a good model for understanding the genetic alteration in tumors because the histologic progression of this tumor is correlated with p53 gene mutation [12] . This study serves to clarify the role of p53 mutations in Taiwanese patients with TCC.
MATERIALS AND METHODS

Tissue samples
From March 1992 to July 2003, specimens were collected from patients with TCC of the bladder, ureter, or renal pelvis, as diagnosed by pathology, at Kaohsiung Medical University Hospital. Patients with a benign diagnosis or with incomplete exon 4-8 analysis data were excluded from the study. All fresh tissue samples were snap-frozen immediately and stored at -80°C until further use.
Histopathology, tumor grades and stages
Standard histopathologic criteria were used to classify tumor grade and stage for each type of cancer. All tumors were graded in accordance with the World Health Organization system [13] . Clinical and pathologic classifications were determined in accordance with the American Joint Committee on Cancer/International Union Against Cancer TNM 1997 criteria [14] . In this system, grade 1 and 2 tumors are defined as low grade and grade 3 and 4 tumors are defined as high grade; tumors of pT1 or less are classified as superficial and those of at least pT2 are classified as invasive.
DNA extraction from tumor tissue
DNA was extracted using the DNeasy TM Tissue Kit (Qiagen, Valencia, CA, USA) and following the manufacturer's recommendations. The tumor tissue was digested with 0.5 mg/mL proteinase K in 400 µL cell-lysis solution for 24 hours at 55°C until the tissue was completely lysed. 200 µL absolute ethanol were added and the mixture transferred into the DNeasy mini column and centrifuged for 1 minute at 8,000 rpm. The DNeasy mini column was washed with 500 µL washing buffer and centrifuged again for 1 minute at 8,000 rpm. Finally, the DNA was eluted into a clean 1.5-mL microcentrifuge tube. The concentration and purity of DNA were determined by measuring the QD at 260 and 280 nm using a spectrophotometer.
Polymerase chain reaction single-strand conformational polymorphism analysis
The highly conserved regions of the p53 gene, exons 4-8, were amplified separately using various intronic oligonucleotide primers ( Table 1 ). The polymerase chain reaction (PCR) was performed using the "hot-start" technique in a final volume of 25 µL reaction buffer containing 50 mM KCl, 1.5 mM MgCl 2 , 10 mM Tris-HCl (pH 9.0 at room temperature), 2 µM EDTA, 0.1 mM dithiothreitol, 1% glycerol, 200 µM each of dATP, dCTP, and dTTP, 50 µM dGTP, 150 µM 7-deaza-dGTP, 10 pmole of each primer, 1.5 U Taq polymerase, and 60 ng genomic DNA in a 0.5-mL polypropylene microtube. After a 35-cycle amplification process (including denaturation for 30 seconds at 94°C, annealing for 30 seconds at 55°C, and extension for 30 seconds at 72°C), 8 µL of amplicons mixed with 8 µL of 2× sample buffer (2× TBE, 0.1% bromophenol blue, 0.1% xylene cyanol, and 10% Ficoll 400) were separated on a 2.5% nondenaturing agarose gel (Amresco, Solon, OH, USA) and visualized using ethidium bromide. For single-strand conformation polymorphism (SSCP) analysis, 4 µL of the PCR product was diluted in 4 µL loading buffer, including 95% formamide, 20 mM ethylenediamine tetraacetic acid, 0.05% bromophenol blue, and 0.5 mL xylene cyanol, heated at 95°C for 3 minutes, and cooled on ice before loading. The electrophoretic analysis was then performed on a Genephor electrophoresis unit (Amersham Pharmacia Biotech, Uppsala, Sweden) using the manufacturer's Genegel Excel 12.5/24 kit, at 5°C for 3-4 hours at 25 mA, 15 W, and 200 V. Finally, the gels were stained in a Hoefer Automated Gel Stainer (Amersham Pharmacia Biotech) with the PlusOne DNA Silver Staining Kit (Amersham Pharmacia Biotech).
DNA sequencing analysis
Sequence analysis was performed using the ABI PRISM TM 310 Genetic Analyzer (Perkin-Elmer Applied Biosystems, Foster City, CA, USA) and the original p53 PCR products. PCR product purified using QIA Quick Purification Columns (Qiagen, Hilden, Germany) was used in Taq cycle sequencing with the Dye Terminator Cycle Sequencing Ready Reaction Kit (ABI Prism, Perkin-Elmer Applied Biosystems), following the manufacturer's instructions. If the presence of a gene mutation was not compatible between SSCP and sequencing, the variant band was selected from the gel and reamplified. To avoid false-positive results due to polymerase errors, PCR products were tested again by performing a new PCR, SSCP, and sequence analysis [15] .
Statistical analysis
Statistical analysis was performed with SPSS version 10.0 (SPSS Inc, Chicago, IL, USA). The Chi-squared test was used to describe the relationship between tumor grade and gene mutation and the correlations among gene mutation, tumor stage, and gender. The t test was used to analyze the relationship between age and gene mutation. A p value of 0.05 or less was chosen as the level of statistical significance.
RESULTS
A total of 94 specimens were collected initially. Thirteen specimens with a benign pathologic diagnosis and six specimens with incomplete exon 4-8 analysis data were excluded from the study. Therefore, 75 patients were enrolled in the study, 54 men and 21 women, with a mean age of 66.85 years (standard deviation, 10.78; range, 26-84 years). Fifty-eight patients had bladder cancer, eight had ureteral cancer, and nine had renal-pelvic cancer. At the time of pathologic diagnosis, 37 tumors were classified as low grade and 38 as high grade. Tumors were superficial in 29 cases and invasive in 46 cases. PCR/SSCP results in exon 4 are shown in Figure 1 . The results of direct sequencing were compatible with those of SSCP analysis (Figure 2) .
A total of 47 patients (62.7%) had p53 gene mutations. Shifted bands Among these, 33 were male and 14 were female. Twentyfour patients with the p53 gene mutation had high-grade tumors and 33 had invasive tumors. Since a significant number of patients (33 of 47, 70.2%) had invasive tumors, it suggests that p53 gene mutations are more common in more highly invasive tumors. Although p53 gene mutations were more prevalent in high-grade than low-grade tumors (24 vs 23), this finding did not reach statistical significance. This indicates that tumor grade is not an important factor associated with p53 gene mutation. p53 gene mutation was more common in male than female patients (33 vs 14), but this difference was not statistically significant, indicating that sex is not a factor influencing p53 gene mutation. The t test revealed no significant relationship between age and p53 gene mutation. Correlations between p53 mutation and possible factors are summarized in Table 2 . Among the 47 patients with p53 gene mutations, 20 (26.7%) had exon 4 mutations, five (6.7%) had exon 5 mutations, 12 (16%) had exon 6 mutations, 17 (22.7%) had exon 7 mutations, and nine (12%) had exon 8 mutations. Furthermore, 14 TCC patients had a mutation in more than one exon. Exon 4 was the most common site of mutation, Table 3 .
Among the 20 patients with exon 4 mutations, 15 (75%) for further analysis. We found that patients with invasive tumors were more likely to have gene mutations, which is consistent with previous reports [20, 21] . However, unlike the relationship between tumor stage and gene mutation, tumor grade was not statistically associated with p53 gene mutation, a finding that conflicts with our understanding of the likelihood of p53 gene mutation in high-grade tumors [9, 22] .
There are three possible reasons for this discrepancy. Surgical specimens were sent for pathologic diagnosis and laboratory examination immediately and individually, so whether the two tumor samples had the same grade classification was difficult to determine. If two samples had different histopathologic characteristics, the malignancy and tumor grade between pathologic diagnosis and our laboratory data might have been different. Another reason may be that most urothelial tumors in this study were from patients with bladder cancer (58 patients), and most of the bladder tumor samples were collected from transurethral resection. In general, resection and coagulation were used during surgery. As a consequence, some tissue, including normal, high-grade, and low-grade tissue, may have been destroyed, thereby influencing the results. The third possibility is that our sample size was not large enough to identify a correlation between tumor grade and p53 gene mutation.
Some reports have stated that previous restrictions to exons 5-8 may have slightly under-represented the true incidence of p53 mutations in colorectal tumors [23] . Reports had invasive tumors and five (25%) had superficial tumors (p = 0.001), nine patients (45%) had high-grade tumors and 11 (55%) had low-grade tumors (p = 0.09). Another interesting finding was that 20 patients had a common polymorphism at codon 72, of which six also had other codon changes in exon 4; the changes in the other 14 existed independently. Among the 20 patients with codon 72 polymorphisms, 16 (80%) had invasive tumors and 14 (70%) had high-grade tumors. Both of these findings were statistically significant (p = 0.000 and 0.005, respectively), indicating that patients with codon 72 polymorphisms are more likely to have invasive or high-grade tumors.
DISCUSSION
In this study, PCR/SSCP analysis and sequencing of exons 4-8 demonstrated that 47 of 75 patients (62.7%) had p53 gene mutations. Of these, 33 (70.2%) had invasive tumors. Our results reveal a higher mutation rate in invasive tumors than previously reported [16, 17] . Habuchi et al noted that p53 mutations are undetectable in 30-50% of clinically advanced urothelial cancers [18] , and reported gene mutation rates of 81% in invasive tumors [19] . These findings suggest that the p53 gene mutation rate is relatively high in patients with invasive tumors. Our findings also showed that a higher p53 mutation rate is directly related to more invasive tumors. However, to verify information about the true mutation rate in the p53 gene, more subjects are needed also indicate that most mutations develop in the core domain of exons 4-9, with some mutations more significant than others with respect to p53 function [24] [25] [26] [27] . However, not all studies were performed in the exon 4-9 region; some reports only examined exons 5-8 [21, 25, 26] . In this study, exon 4 of the p53 gene was the most common mutation site, with multiple mutation sites including codons 36, 49, 51, 52, 54, 56, 59, 61, 62, 65, 66, 67, 97, 101, 108, and 120. Codon 72 abnormalities, thought to be normal polymorphisms, were also noted.
Some researchers have described an analysis of exons 4-9 of p53 gene mutations without stating the highest mutation rate [24] . Other reports have indicated that exon 8 was the most common mutation site in exon-5-8 analyses [22, 25, 26] . Among the 75 patients examined for exon 4-8 mutations in this study, 20 (26.7%) had an exon 4 mutation. In addition, almost 75% of patients with exon 4 mutations had invasive tumors, indicating that they are closely related. For these reasons, exon 4 mutation is worthy of further attention.
Among the 20 patients with codon 72 polymorphisms, 16 (80%) had invasive tumors and 14 (70%) had high-grade tumors. Both of these findings reached statistical significance. This suggests that codon 72 polymorphism is closely related to invasive tumors and to high-grade tumors. It may also imply a relationship between codon 72 polymorphism and tumor progression, prognosis, and drug response.
CONCLUSION
In this study, 62.7% of TCC patients had a p53 mutation. Additionally, being observed in 71.7% of the pT2 or greater cases, invasive tumors were significantly more likely to have a p53 gene mutation. In this study, age and sex were not important risk factors associated with p53 gene mutation. Although more high-grade than low-grade tumors had a p53 gene mutation, it did not reach statistical significance. These results indicate that p53 gene mutation may be used as a marker of TCC. Simple analysis of the p53 gene using PCR/SSCP is suitable for screening for p53 abnormalities in TCC. The findings also suggest that the relationship between cancer risk and codon 72 polymorphism in exon 4 needs further investigation. 
